Clinical Trial

A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059)

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 8, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This retrospective real-world study aims to evaluate the efficacy and safety of anlotinib hydrochloride combined with immunotherapy as maintenance therapy following standard chemoimmunotherapy in extensive-stage small cell lung cancer (ES-SCLC).The study population consists of treatment-naïve ES-SCLC patients who did not progress after induction chemoimmunotherapy and subsequently received maintenance therapy with anlotinib plus immunotherapy. The primary objectives are progression-free survival (PFS)，overall survival (OS) , and safety.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-20.
Trial Details
NCT Number NCT06982287
Lead Sponsor Yong Fang
Conditions Small Cell Lung Cancer Extensive Stage
Enrollment 100 participants
Start Date 2025-08-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-08